Adrenergic modifiers - Biotech, Pharma and Life Science Channel

21:01 EDT 30th July 2015 | BioPortfolio

PubMed Articles [355 Associated PubMed Articles listed on BioPortfolio]

Impaired mitochondrial energy supply coupled to increased H2O2 emission under energy/redox stress leads to myocardial dysfunction during Type I diabetes.

In Type I diabetic (T1DM) patients, both peaks of hyperglycaemia and increased sympathetic tone probably contribute to impair systolic and diastolic function. However, how these stressors eventually ...

Preservation properties of in situ modified CaCO3-chitosan composite coatings.

To improve the dispersibility, hydrophilia constraints of primitive particle size, and reduce the economic cost, in situ modified CaCO3-chitosan composite coatings were prepared by tape-casting with d...

Cardiovascular Autonomic Dysfunction in Chronic Kidney Disease: a Comprehensive Review.

Cardiovascular autonomic dysfunction is a major complication of chronic kidney disease (CKD), likely contributing to the high incidence of cardiovascular mortality in this patient population. In addit...

Biological therapies for atrial fibrillation: ready for prime time?

Atrial fibrillation is a prominent cause of morbidity and mortality in developed countries. Treatment strategies center on controlling atrial rhythm or ventricular rate. The need for anticoagulation i...

Combining Epinephrine and Esmolol Attenuates Excessive Autophagy and Mitophagy in Rat Cardiomyocytes Following Cardiac Arrest.

Recent experimental and clinical studies have indicated that the β-adrenergic effect of epinephrine significantly increases the severity of post-resuscitation myocardial dysfunction. The aim of this ...

Genetic Modifiers of Age at Onset in Carriers of the G206A Mutation in PSEN1 With Familial Alzheimer Disease Among Caribbean Hispanics.

The present study identified potential genetic modifiers that may delay or accelerate age at onset of familial Alzheimer disease (AD) by examining age at onset in PSEN1 mutation carrier families, and ...

Expression Profiles of Neuropeptides, Neurotransmitters, and Their Receptors in Human Keratocytes In Vitro and In Situ.

Keratocytes, the quiescent cells of the corneal stroma, play a crucial role in corneal wound healing. Neuropeptides and neurotransmitters are usually associated with neuronal signaling, but have recen...

Histone lysine demethylases in Drosophila melanogaster.

Epigenetic regulation of chromatin structure is a fundamental process for eukaryotes. Regulators include DNA methylation, microRNAs and chromatin modifications. Within the chromatin modifiers, one cla...

β-Adrenergic Receptors Suppress Rap1B Prenylation and Promote the Metastatic Phenotype in Breast Cancer Cells.

A greater understanding of the molecular basis of breast cancer metastasis will lead to identification of novel therapeutic targets and better treatments. Rap1B is a small GTPase that suppresses the m...

Sound of silence: the properties and functions of repressive Lys methyltransferases.

The methylation of histone Lys residues by Lys methyltransferases (KMTs) regulates chromatin organization and either activates or represses gene expression, depending on the residue that is targeted. ...

News Articles [38 Associated News Articles listed on BioPortfolio]

GSK discusses pipeline expectations, growing HIV sales

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) CEO Andrew Witty said on the company's 2Q15 earnings call that the company has about 40 drug candidates in its pipeline, with 20-25 that could be approved in th...

Recro's Dex-IN meets in Phase II pain study

Recro Pharma Inc. (NASDAQ:REPH) gained $0.65 to $16.58 after it said Dex-IN met the primary endpoint of a Phase II trial to treat acute pain in patients undergoing bunionectomy.The intranasal formulat...

Inhaled Formoterol Prevents Hypoglycemia in Diabetes Study

The specific beta-2 adrenergic receptor agonist is already available in inhaled form for asthma and could also be a help to patients with type 1 diabetes and hypoglycemia unawareness. Medscape M...

Personal Care Ingredients (Surfactants, Conditioning Polymers, Emollients, Rheology Modifiers and Others) Market 2015-2020

Dublin, July 08, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/7hqnsp/personal_care) has announced the addition of the

TES Pharma and École Polytechnique Fédérale de Lausanne (EPFL) Announce R&D Collaboration on Small Molecule Therapies for Metabolic Disorders and Age-Related Diseases

PERUGIA, Italy and LAUSANNE, Switzerland, July 2, 2015 /PRNewswire/ -- TES Pharma and EPFL announce a new research and development collaboration on novel small molecule modulators of the kynurenine p...

Rheology Modifiers (Organic and Inorganic) Market 2015-2020 - Paints & Coatings, Cosmetics & Personal Care, Adhesives & Sealants, Inks, Pharmaceuticals, HI&I Products, Oil & Gas, and Construction

Dublin, July 01, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/pssx2q/rheology) has announced the addition of the

Allergan sues hedge fund in response to Combigan IPR

Allergan plc (NYSE:AGN) filed suit against Ferrum Ferro Capital in the U.S. District Court for the Central District of California, alleging the hedge fund attempted to extort the company "by misusing ...

Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms

Myeloproliferative neoplasms (MPNs) are diseases caused by mutations in the haematopoietic stem cell (HSC) compartment. Most MPN patients have a common acquired mutation of Janus kinase 2 (JAK2) gene ...

Onxeo Consolidates Its Industrial Property with a US Patent Protecting Validive® until 2029

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today annou...

Aerie rebounds after FDA clears IOP endpoint

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) gained $6.64 (50%) to $19.91 on Tuesday after it said FDA will allow the company to change the primary endpoint of the Phase III Rocket 2 trial of glaucoma tre...

Events [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Innate Immunotherapeutics Limited

Innate Immunotherapeutics Limited is a public unlisted biopharmaceutical company based in Auckland, New Zealand. The company is focused on the development of a new generation of i...

Innate Therapeutics Limited

Innate Therapeutics Limited is a public unlisted biopharmaceutical company based in Auckland. The company is focused on the development of a new generation of immune response modi...

Clinical Trials [94 Associated Clinical Trials listed on BioPortfolio]

Improving Beta-2 Adrenergic Signaling in Alzheimers Disease

The purpose of this study is to test the effects of long-term therapeutic doses of formoterol, on a) cerebrospinal fluid (CSF) tau levels, and Amyloid Beta protein 40/42 levels in the CSF,...

Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response

Essential Tremor (ET) is the most common tremor disorder, currently affecting an estimated 2.9 million Americans and leading to disability and decreased quality of life in 75% of cases. Th...

Doxazosin for PTSD and Alcohol Use Disorder

The study will test the efficacy of doxazosin, a long-acting and selective alpha-1 adrenergic antagonist, as compared to placebo in reducing PTSD symptomatology and alcohol use severity.

Echocardiographic Evaluation of the Effects of Dexmedetomidine in Diastolic Dysfunction

Dexmedetomidine is a selective α2 adrenergic agonist that can be considered a primary anesthetic, an adjuvant to propofol or inhalational anesthetics. Dexmedetomidine mediate its cardiova...

Spinal Manipulative Therapy Treatment Effect Modifiers in Individuals With Low Back Pain

This study considers whether treatment effects in response to spinal manipulative therapy for individuals experiencing low back pain are dependent upon the context in which the interventio...

DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury

The investigators intend to determine the effect of adrenergic blockade on 1) short-term physiology, behavior, and cognition and 2) long-term neuropsychological outcomes after severe Traum...

Therapeutic Response Evaluation and Adherence Trial (TREAT)

The primary objectives of this prospective study of hydroxyurea for children with sickle cell anemia are 1) Develop and prospectively evaluate a population pharmacokinetic/pharmacodynamics...

Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse

Cocaine use disorders affect approximately 1.5 million Americans annually. Currently, there are no US Food and Drug Administration approved medications for treatment of cocaine dependence;...

Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD)

Understanding what treatments may facilitate perioperative care of Veterans with posttraumatic stress disorder (PTSD) is of great importance to the U.S. health care system. Patients with ...

Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury

The primary purpose of this study is to determine the effect of administration of the oral beta-2 adrenergic agonist, albuterol, on respiratory muscle strength in individuals with cervical...

Videos

None available.

Medical and Biotech [MESH] Definitions

Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.

Drugs that bind to but do not activate ADRENERGIC RECEPTORS. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters EPINEPHRINE and NOREPINEPHRINE.

A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). beta-3 Adrenergic receptors are the predominant beta-adrenergic receptor type expressed in white and brown ADIPOCYTES and are involved in modulating ENERGY METABOLISM and THERMOGENESIS.

Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.


Advertisement
 
Advertisement
 
review and buy Adrenergic modifiers market research data and corporate reports here

Channels Quicklinks